James E. Dentzer - 20 May 2025 Form 4 Insider Report for CURIS INC (CRIS)

Reporting relationship: President & CEO, Director
Issuer ticker: CRIS
Reported as of: 20 May 2025
Net transaction value: +$1,126,800
SEC form: 4
Accepted by SEC: 22 May 2025, 16:13:54 UTC
Prior SEC filing: 18 Mar 2025
Next SEC filing: 06 Aug 2025
Source filing: View source filing
Reporting owner signature: /s/ Diantha Duvall, Attorney-in-fact

Key filing fact

James E. Dentzer filed Form 4 for CURIS INC (CRIS) on 22 May 2025.

Key facts

This page summarizes James E. Dentzer's Form 4 filing for CURIS INC (CRIS).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 22 May 2025, 16:13.

Change

Previous filing in this sequence was filed on 18 Mar 2025.
Current net transaction value: +$1,126,800.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001400977 Primary reporting owner

Dentzer James E

Relationship: President & CEO, Director
Address: 128 SPRING STREET, BUILDING C - SUITE 500, LEXINGTON
Signature: /s/ Diantha Duvall, Attorney-in-fact
Signature date: 22 May 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CRIS transaction Derivative

Employee stock option (right to buy)

Award

Transaction value: $1,126,800
Shares: +360,000
Change %
Price: $3.13
Shares after: 360,000
Date: 20 May 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 360,000
Exercise price: $3.13
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

This option grant, as disclosed in Curis Inc.'s 2025 proxy statement, was approved by the Board of Directors of Curis, Inc. on January 28, 2025, contingent upon shareholder approval of Curis's Amendment No. 1 to the Fifth Amended and Restated 2010 Stock Incentive Plan to increase the number of shares authorized for issuance thereunder; and further provided that such option would not be exercisable and no common stock would be issued thereunder, if Amendment No. 1 to the Fifth Amended and Restated 2010 Plan was not approved by Curis's shareholders. On May 20, 2025, at the 2025 annual meeting of shareholders, Curis's shareholders approved Amendment No. 1 to the Fifth Amended and Restated 2010 Plan.

Footnote F2

The option grant described in this Form 4 filing vests as to 25% of the original shares on January 28, 2026 and as to an additional 6.25% of the original shares each successive quarter and until January 28, 2029.